Patients with a clinical diagnosis of depression who in the judgement of their physician require medication management may be eligible for enrollment. A score of 10 or more on the PHQ-9 instrument will be required for enrollment.
Some practices utilize the PHQ-2 and PHQ-9 are part of routine screening for depression. If the tests are performed routinely, they do not need to be repeated for study eligibility, and may be performed prior to informed consent for this study. If, however, the PHQ-9 is not routinely performed, informed consent must be performed prior to administration. Patients with a score below 10 will be considered screen failures and will not be enrolled or offered the MYnd testing.
Patients with non-psychotic comorbid conditions may be included.
Patients must be either medication treatment naïve for behavioral illnesses or have no active medication treatments for at least 1 month prior to enrollment. Prohibited medications at the time of enrollment will include stimulants, benzodiazepines and THC. Prior therapy with these agents is permitted with a washout of >30 days.
Patients must have private medical insurance coverage through Horizon Blue Cross Blue Shield. This is limited to insured commercial members, including HMO, and excluding, for the avoidance of doubt, members of self-insured customers or Medicare or Medicaid programs.

NCT03328052_inc_T1
Condition
depression
NCT03328052_inc_T2
Drug
medication
NCT03328052_inc_T3
Measurement
PHQ-9
NCT03328052_inc_T4
Value
score of 10 or more
NCT03328052_inc_T6
Condition
n-psychotic c nditions m
NCT03328052_inc_T7
Drug
medication
NCT03328052_inc_T8
Condition
behavioral illnesses
NCT03328052_inc_T9
Negation
naïve
NCT03328052_inc_T10
Negation
no
NCT03328052_inc_T11
Qualifier
active
NCT03328052_inc_T12
Drug
medication
NCT03328052_inc_T13
Temporal
for at least 1 month prior to enrollment
NCT03328052_inc_T14
Drug
benzodiazepines
NCT03328052_inc_T15
Drug
THC
NCT03328052_inc_T16
Drug
stimulants